Percutaneous needle fasciotomy versus limited fasciectomy in Dupuytren's disease

Percutaneous needle fasciotomy versus limited fasciectomy in Dupuytren's disease: A randomised controlled clinical trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN58554745

Enrollment

120

Registered

2011-06-06

Start date

2002-08-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dupuytren's disease Musculoskeletal Diseases Fibroblastic disorders

Interventions

Patients were randomised to one of the following treatments 1. Percutaneous needle fasciotomy 2. Limited fasciectomy All patients were treated only once, within 1 month of inclusion. All were seen i

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with Dupuytren?s disease presenting at the Department for Plastic, Reconstructive and Hand Surgery of the Isala Klinieken, Zwolle from August 2002 2. Total passive extension deficit of at least 30° in the metacarpophalangeal (MCP) joint, proximal interphalangeal (PIP) joint and/or distal interphalangeal (PIP) joint 3. Existence of a clearly defined palmar cord 4. Willingness to participate in this trial. Following counselling written consent was obtained from all patients that entered the study

Exclusion criteria

Exclusion criteria: 1. Postsurgical recurrence or extension of the disease 2. Patients who were not allowed to stop their anticoagulants 3. Generally unfit for surgery 4. Patients with a specific treatment modality wish

Design outcomes

Primary

Measure	Time frame
1. Treatment results: Total Passive Extension Deficit (degrees) assessed postoperatively at 1 week, 6 weeks, 6 months, and then yearly for 5 years 2. Recurrence: Recurrence was defined as an increase of total passive extension deficit of at least 30 degrees compared to the 6 weeks follow-up values in the area previously treated. At the time of registration patients suffering from recurrent disease and treated for recurrence, are still in follow-up.	—

Measure

Time frame

1. Treatment results: Total Passive Extension Deficit (degrees) assessed postoperatively at 1 week, 6 weeks, 6 months, and then yearly for 5 years 2. Recurrence: Recurrence was defined as an increase of total passive extension deficit of at least 30 degrees compared to the 6 weeks follow-up values in the area previously treated. At the time of registration patients suffering from recurrent disease and treated for recurrence, are still in follow-up.

—

Secondary

Measure	Time frame
1. Flexion (Boyes, cm) assessed postoperatively at 1 week, 6 weeks, 6 months, and then yearly for 5 years 2. Sensibility (Semmes-Weinstein) assessed postoperatively at 1 week, 6 weeks, 6 months, and then yearly for 5 years 3. Complications assessed postoperatively at 1 week, 6 weeks, 6 months, and then yearly for 5 years 4. Satisfaction (scale) assessed by questionnaire at 1, 2, 3, 4, 5, 6 weeks, and 6 months, and thereafter yearly until 5 years	—

Measure

Time frame

1. Flexion (Boyes, cm) assessed postoperatively at 1 week, 6 weeks, 6 months, and then yearly for 5 years 2. Sensibility (Semmes-Weinstein) assessed postoperatively at 1 week, 6 weeks, 6 months, and then yearly for 5 years 3. Complications assessed postoperatively at 1 week, 6 weeks, 6 months, and then yearly for 5 years 4. Satisfaction (scale) assessed by questionnaire at 1, 2, 3, 4, 5, 6 weeks, and 6 months, and thereafter yearly until 5 years

—

Countries

Netherlands

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026